MIRUM PHARMACEUTICALS INC (MIRM) Stock Fundamental Analysis

NASDAQ:MIRM • US6047491013

107.48 USD
+1.59 (+1.5%)
At close: Feb 24, 2026
107.7 USD
+0.22 (+0.2%)
After Hours: 2/24/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall MIRM gets a fundamental rating of 4 out of 10. We evaluated MIRM against 521 industry peers in the Biotechnology industry. While MIRM seems to be doing ok healthwise, there are quite some concerns on its profitability. MIRM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year MIRM has reported negative net income.
  • MIRM had a positive operating cash flow in the past year.
  • In the past 5 years MIRM always reported negative net income.
  • MIRM had negative operating cash flow in 4 of the past 5 years.
MIRM Yearly Net Income VS EBIT VS OCF VS FCFMIRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of MIRM (-5.30%) is better than 86.18% of its industry peers.
  • Looking at the Return On Equity, with a value of -14.26%, MIRM belongs to the top of the industry, outperforming 86.95% of the companies in the same industry.
Industry RankSector Rank
ROA -5.3%
ROE -14.26%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
MIRM Yearly ROA, ROE, ROICMIRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • MIRM's Gross Margin of 79.92% is amongst the best of the industry. MIRM outperforms 85.41% of its industry peers.
  • In the last couple of years the Gross Margin of MIRM has declined.
  • MIRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
MIRM Yearly Profit, Operating, Gross MarginsMIRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MIRM has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MIRM has been increased compared to 5 years ago.
  • Compared to 1 year ago, MIRM has an improved debt to assets ratio.
MIRM Yearly Shares OutstandingMIRM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MIRM Yearly Total Debt VS Total AssetsMIRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 6.47 indicates that MIRM is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.47, MIRM is in the better half of the industry, outperforming 75.43% of the companies in the same industry.
  • MIRM has a debt to FCF ratio of 6.97. This is a slightly negative value and a sign of low solvency as MIRM would need 6.97 years to pay back of all of its debts.
  • MIRM's Debt to FCF ratio of 6.97 is amongst the best of the industry. MIRM outperforms 91.17% of its industry peers.
  • MIRM has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of MIRM (1.06) is worse than 75.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 6.97
Altman-Z 6.47
ROIC/WACCN/A
WACC8.39%
MIRM Yearly LT Debt VS Equity VS FCFMIRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • MIRM has a Current Ratio of 3.31. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.31, MIRM is not doing good in the industry: 60.65% of the companies in the same industry are doing better.
  • A Quick Ratio of 3.16 indicates that MIRM has no problem at all paying its short term obligations.
  • MIRM has a Quick ratio of 3.16. This is in the lower half of the industry: MIRM underperforms 60.27% of its industry peers.
Industry RankSector Rank
Current Ratio 3.31
Quick Ratio 3.16
MIRM Yearly Current Assets VS Current LiabilitesMIRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 57.43% over the past year.
  • MIRM shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.66%.
  • MIRM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.12% yearly.
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%

3.2 Future

  • Based on estimates for the next years, MIRM will show a very strong growth in Earnings Per Share. The EPS will grow by 31.74% on average per year.
  • The Revenue is expected to grow by 25.40% on average over the next years. This is a very strong growth
EPS Next Y85%
EPS Next 2Y39.15%
EPS Next 3Y31.86%
EPS Next 5Y31.74%
Revenue Next Year53.97%
Revenue Next 2Y38.16%
Revenue Next 3Y31.77%
Revenue Next 5Y25.4%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MIRM Yearly Revenue VS EstimatesMIRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
MIRM Yearly EPS VS EstimatesMIRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MIRM. In the last year negative earnings were reported.
  • Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRM Price Earnings VS Forward Price EarningsMIRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, MIRM is valued cheaply inside the industry as 90.98% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 125.09
EV/EBITDA N/A
MIRM Per share dataMIRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • MIRM's earnings are expected to grow with 31.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.15%
EPS Next 3Y31.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MIRM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (2/24/2026, 8:00:01 PM)

After market: 107.7 +0.22 (+0.2%)

107.48

+1.59 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-11
Inst Owners99.71%
Inst Owner Change5.21%
Ins Owners1.66%
Ins Owner Change0.51%
Market Cap5.55B
Revenue(TTM)471.79M
Net Income(TTM)-41.63M
Analysts86.25
Price Target116.99 (8.85%)
Short Float %18.17%
Short Ratio9.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.86%
Min EPS beat(2)63.96%
Max EPS beat(2)129.77%
EPS beat(4)3
Avg EPS beat(4)26.25%
Min EPS beat(4)-99.42%
Max EPS beat(4)129.77%
EPS beat(8)4
Avg EPS beat(8)-5.65%
EPS beat(12)7
Avg EPS beat(12)-12.67%
EPS beat(16)10
Avg EPS beat(16)-42.14%
Revenue beat(2)2
Avg Revenue beat(2)8.03%
Min Revenue beat(2)0.25%
Max Revenue beat(2)15.82%
Revenue beat(4)4
Avg Revenue beat(4)7.03%
Min Revenue beat(4)0.25%
Max Revenue beat(4)15.82%
Revenue beat(8)7
Avg Revenue beat(8)4.34%
Revenue beat(12)11
Avg Revenue beat(12)8.01%
Revenue beat(16)13
Avg Revenue beat(16)3.12%
PT rev (1m)10.5%
PT rev (3m)39.88%
EPS NQ rev (1m)759.01%
EPS NQ rev (3m)152.04%
EPS NY rev (1m)14.73%
EPS NY rev (3m)60.13%
Revenue NQ rev (1m)1.16%
Revenue NQ rev (3m)3.32%
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)1.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.77
P/FCF 125.09
P/OCF 124.1
P/B 19.02
P/tB 92.34
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)0.86
FCFY0.8%
OCF(TTM)0.87
OCFY0.81%
SpS9.13
BVpS5.65
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.3%
ROE -14.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.92%
FCFM 9.41%
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 6.97
Debt/EBITDA N/A
Cap/Depr 1.46%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.31
Quick Ratio 3.16
Altman-Z 6.47
F-Score6
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y85%
EPS Next 2Y39.15%
EPS Next 3Y31.86%
EPS Next 5Y31.74%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
Revenue Next Year53.97%
Revenue Next 2Y38.16%
Revenue Next 3Y31.77%
Revenue Next 5Y25.4%
EBIT growth 1Y56.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.22%
EBIT Next 3Y33.68%
EBIT Next 5YN/A
FCF growth 1Y142.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y150.52%
OCF growth 3YN/A
OCF growth 5YN/A

MIRUM PHARMACEUTICALS INC / MIRM FAQ

What is the fundamental rating for MIRM stock?

ChartMill assigns a fundamental rating of 4 / 10 to MIRM.


What is the valuation status for MIRM stock?

ChartMill assigns a valuation rating of 2 / 10 to MIRUM PHARMACEUTICALS INC (MIRM). This can be considered as Overvalued.


Can you provide the profitability details for MIRUM PHARMACEUTICALS INC?

MIRUM PHARMACEUTICALS INC (MIRM) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for MIRM stock?

The Earnings per Share (EPS) of MIRUM PHARMACEUTICALS INC (MIRM) is expected to grow by 85% in the next year.